Intellia Therapeutics Stock Forecast, Price & News

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Intellia Therapeutics stock.
View analyst ratings for Intellia Therapeutics or view top-rated stocks.

Wall Street analysts have given Intellia Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intellia Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Intellia Therapeutics.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its quarterly earnings results on Thursday, May, 6th. The company reported ($0.69) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.66) by $0.03. The business had revenue of $6.45 million for the quarter, compared to the consensus estimate of $8.57 million. Intellia Therapeutics had a negative net margin of 288.47% and a negative trailing twelve-month return on equity of 33.89%. Intellia Therapeutics's quarterly revenue was down 50.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.63) earnings per share.
View Intellia Therapeutics' earnings history.

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NTLA stock has increased by 570.5% and is now trading at $85.29.
View which stocks have been most impacted by COVID-19.

14 equities research analysts have issued twelve-month target prices for Intellia Therapeutics' stock. Their forecasts range from $33.00 to $111.00. On average, they anticipate Intellia Therapeutics' share price to reach $79.00 in the next twelve months. This suggests that the stock has a possible downside of 7.4%.
View analysts' price targets for Intellia Therapeutics or view top-rated stocks among Wall Street analysts.

12 employees have rated Intellia Therapeutics CEO John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among Intellia Therapeutics' employees.

Some companies that are related to Intellia Therapeutics include Ipsen (IPSEY), Quidel (QDEL), Neogen (NEOG), Ortho Clinical Diagnostics (OCDX), Myriad Genetics (MYGN), Heska (HSKA), Lantheus (LNTH), Celldex Therapeutics (CLDX), Meridian Bioscience (VIVO), Aspira Women's Health (AWH), OncoCyte (OCX), Quotient (QTNT), Lucira Health (LHDX), VolitionRx (VNRX) and MyMD Pharmaceuticals (MYMD).
View all of NTLA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Intellia Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (14.10%), BlackRock Inc. (7.74%), Nikko Asset Management Americas Inc. (7.11%), Sumitomo Mitsui Trust Holdings Inc. (7.10%), Price T Rowe Associates Inc. MD (3.41%) and Alliancebernstein L.P. (2.58%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, Caroline Dorsa, Jean Francois Formela, John M Leonard, Jose E Rivera and Perry A Karsen.
View institutional ownership trends for Intellia Therapeutics.

NTLA stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Morgan Stanley, Chevy Chase Trust Holdings Inc., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Capital Impact Advisors LLC, Royal Bank of Canada, and UBS Group AG. Company insiders that have sold Intellia Therapeutics company stock in the last year include Andrew Schiermeier, Caroline Dorsa, Jean Francois Formela, John M Leonard, Jose E Rivera, and Perry A Karsen.
View insider buying and selling activity for Intellia Therapeutics or view top insider-selling stocks.

NTLA stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Jennison Associates LLC, Lord Abbett & CO. LLC, Nomura Holdings Inc., JPMorgan Chase & Co., PFM Health Sciences LP, Compagnie Lombard Odier SCmA, and BlackRock Inc..
View insider buying and selling activity for Intellia Therapeutics or or view top insider-buying stocks.

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NTLA stock can currently be purchased for approximately $85.29.

Intellia Therapeutics has a market capitalization of $5.81 billion and generates $57.99 million in revenue each year. The company earns $-134,230,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.

Intellia Therapeutics employs 312 workers across the globe.

The official website for Intellia Therapeutics is www.intelliatx.com.

Intellia Therapeutics is headquartered at 40 Erie Street Suite 130, Cambridge MA, 02139.

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]